Seagrave Pharma Consultancy Ltd. 08104629 false 2023-07-01 2024-09-16 2024-09-16 The principal activity of the company is consultancy services to the Pharmaceutical Industry. Digita Accounts Production Advanced 6.30.9574.0 true true 08104629 2023-07-01 2024-09-16 08104629 2024-09-16 08104629 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2024-09-16 08104629 core:RetainedEarningsAccumulatedLosses 2024-09-16 08104629 core:ShareCapital 2024-09-16 08104629 core:CurrentFinancialInstruments 2024-09-16 08104629 core:CurrentFinancialInstruments core:WithinOneYear 2024-09-16 08104629 core:FurnitureFittingsToolsEquipment 2024-09-16 08104629 bus:SmallEntities 2023-07-01 2024-09-16 08104629 bus:AuditExemptWithAccountantsReport 2023-07-01 2024-09-16 08104629 bus:FilletedAccounts 2023-07-01 2024-09-16 08104629 bus:SmallCompaniesRegimeForAccounts 2023-07-01 2024-09-16 08104629 bus:RegisteredOffice 2023-07-01 2024-09-16 08104629 bus:Director1 2023-07-01 2024-09-16 08104629 bus:Director2 2023-07-01 2024-09-16 08104629 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2023-07-01 2024-09-16 08104629 bus:PrivateLimitedCompanyLtd 2023-07-01 2024-09-16 08104629 core:FurnitureFittings 2023-07-01 2024-09-16 08104629 core:OfficeEquipment 2023-07-01 2024-09-16 08104629 countries:England 2023-07-01 2024-09-16 08104629 2023-06-30 08104629 core:FurnitureFittingsToolsEquipment 2023-06-30 08104629 2022-07-01 2023-06-30 08104629 2023-06-30 08104629 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2023-06-30 08104629 core:RetainedEarningsAccumulatedLosses 2023-06-30 08104629 core:ShareCapital 2023-06-30 08104629 core:CurrentFinancialInstruments 2023-06-30 08104629 core:CurrentFinancialInstruments core:WithinOneYear 2023-06-30 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 08104629

Seagrave Pharma Consultancy Ltd.

Unaudited Filleted Financial Statements

for the Period from 1 July 2023 to 16 September 2024

 

Seagrave Pharma Consultancy Ltd.

Contents

Company Information

1

Balance Sheet

2

Notes to the Unaudited Financial Statements

3 to 7

 

Seagrave Pharma Consultancy Ltd.

Company Information

Directors

Mr D Garton

Mrs K Garton

Registered office

Barton View
Lapford
Devon
EX17 6PZ

Accountants

Clever Accounts Limited
Brookfield Court
Selby Road
Leeds
LS25 1NB

 

Seagrave Pharma Consultancy Ltd.

(Registration number: 08104629)
Balance Sheet as at 16 September 2024

Note

2024
£

2023
£

Current assets

 

Debtors

5

48,429

69,078

Investments

6

75,630

136,043

Cash at bank and in hand

 

370,298

180,805

 

494,357

385,926

Creditors: Amounts falling due within one year

7

(62,467)

(37,911)

Net assets

 

431,890

348,015

Capital and reserves

 

Called up share capital

8

10

10

Retained earnings

431,880

348,005

Shareholders' funds

 

431,890

348,015

For the financial period ending 16 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 4 October 2024 and signed on its behalf by:
 

.........................................

Mr D Garton
Director

 

Seagrave Pharma Consultancy Ltd.

Notes to the Unaudited Financial Statements for the Period from 1 July 2023 to 16 September 2024

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
Barton View
Lapford
Devon
EX17 6PZ

These financial statements were authorised for issue by the Board on 4 October 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

 

Seagrave Pharma Consultancy Ltd.

Notes to the Unaudited Financial Statements for the Period from 1 July 2023 to 16 September 2024

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Fixture and Fittings

25% Straight line

Office Equipment

3 Years Straight Line

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

 

Seagrave Pharma Consultancy Ltd.

Notes to the Unaudited Financial Statements for the Period from 1 July 2023 to 16 September 2024

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including directors) during the period, was 2 (2023 - 2).

 

Seagrave Pharma Consultancy Ltd.

Notes to the Unaudited Financial Statements for the Period from 1 July 2023 to 16 September 2024

4

Tangible assets

Furniture, fittings and equipment
 £

Total
£

Cost or valuation

At 1 July 2023

2,528

2,528

At 16 September 2024

2,528

2,528

Depreciation

At 1 July 2023

2,528

2,528

At 16 September 2024

2,528

2,528

Carrying amount

At 16 September 2024

-

-

5

Debtors

Current

2024
£

2023
£

Trade debtors

40,862

67,741

Other debtors

7,567

1,337

 

48,429

69,078

6

Current asset investments

2024
£

2023
£

Other investments

75,630

136,043

7

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Due within one year

Taxation and social security

61,987

37,911

Accruals and deferred income

480

-

62,467

37,911

 

Seagrave Pharma Consultancy Ltd.

Notes to the Unaudited Financial Statements for the Period from 1 July 2023 to 16 September 2024

8

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary shares of £1 each

10

10

10

10